NYSE:NVTA (USA) Also trade in: Germany UK

Invitae Corp

$ 24.22 -0.56 (-2.26%)
Volume: 1,568,022 Avg Vol (1m): 1,787,933
Market Cap $: 2.27 Bil Enterprise Value $: 2.07 Bil
P/E (TTM): 0.00 P/B: 6.06
Earnings Power Value -64.06
Net Current Asset Value 2.03
Tangible Book 2.99
Projected FCF 0
Median P/S Value 24.06
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6.4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 3.62
Cash-To-Debt range over the past 10 years
Min: 0.82, Med: 5.17, Max: 57.46
Current: 3.62
0.82
57.46
Equity-to-Asset 0.66
Equity-to-Asset range over the past 10 years
Min: -0.7, Med: 0.65, Max: 0.95
Current: 0.66
-0.7
0.95
Debt-to-Equity 0.25
Debt-to-Equity range over the past 10 years
Min: -0.1, Med: 0.18, Max: 0.66
Current: 0.25
-0.1
0.66
Debt-to-EBITDA -0.69
Debt-to-EBITDA range over the past 10 years
Min: -0.7, Med: -0.15, Max: -0.08
Current: -0.69
-0.7
-0.08
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 6.67
DISTRESS
GREY
SAFE
Beneish M-Score -2.61
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -105.12%
WACC 19.83%

Profitability & Growth : 6/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -76.15
Operating Margin range over the past 10 years
Min: -16725, Med: -733.98, Max: -76.15
Current: -76.15
-16725
-76.15
Net Margin % -81.52
Net Margin range over the past 10 years
Min: -16782.43, Med: -735.95, Max: -81.52
Current: -81.52
-16782.43
-81.52
ROE % -72.87
ROE range over the past 10 years
Min: -327.67, Med: -101.47, Max: -72.87
Current: -72.87
-327.67
-72.87
ROA % -43.89
ROA range over the past 10 years
Min: -72.21, Med: -62.82, Max: -33.12
Current: -43.89
-72.21
-33.12
ROC (Joel Greenblatt) % -384.61
ROC (Joel Greenblatt) range over the past 10 years
Min: -521.05, Med: -449.19, Max: -313.52
Current: -384.61
-521.05
-313.52
3-Year Total Revenue Growth Rate 160.30
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 147.95, Max: 322.7
Current: 95.3
0
322.7
3-Year Total EBITDA Growth Rate -9.80
3-Year EBITDA Growth Rate range over the past 10 years
Min: -75, Med: -18.75, Max: 17.6
Current: 17.6
-75
17.6
3-Year EPS w/o NRI Growth Rate 15.20
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -3.7, Max: 15.2
Current: 15.2
0
15.2

» NVTA's 30-Y Financials

Financials (Next Earnings Date: 2019-08-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:NVTA

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Medical Diagnostics & Research    NAICS : 621511    SIC : 8071
Compare AMEX:SENS XKRX:038290 OSTO:CEVI NAS:OXFD XKRX:180400 ROCO:4103 NAS:PACB TSE:2309 NYSE:ENZ NSE:THYROCARE MEX:MEDICA B NAS:SRDX TSE:4595 ASX:IDX NAS:NTRA NAS:QTNT ISX:PRDA NAS:FLDM XKRX:086040 NAS:TTOO
Traded in other countries IV8.Germany 0JDB.UK
Address 1400 16th Street, San Francisco, CA, USA, 94103
Invitae Corp provides genetic testing services that screen for a variety of conditions, including cardiovascular, neurology, and pediatric disorders, hereditary cancer, and rare diseases. The firm consolidates several genetic tests into a single offering, which is often sold at a lower prices than other single- or multi-gene panels. Invitae typically charges one price per indication, regardless of the number of genes tested. It also offers full gene sequencing and deletion and duplication analysis for its tests. Invitae currently markets its test to medical geneticists and genetic counselors. The majority of Invitae's revenue is generated in the United States.

Ratios

Current vs industry vs history
PB Ratio 6.06
PB Ratio range over the past 10 years
Min: 1.31, Med: 3.64, Max: 8.91
Current: 6.06
1.31
8.91
PS Ratio 11.01
PS Ratio range over the past 10 years
Min: 2.75, Med: 10.95, Max: 131.69
Current: 11.01
2.75
131.69
EV-to-EBIT -16.15
EV-to-EBIT range over the past 10 years
Min: -16.63, Med: -3.05, Max: -0.2
Current: -16.15
-16.63
-0.2
EV-to-EBITDA -18.03
EV-to-EBITDA range over the past 10 years
Min: -18.55, Med: -3.3, Max: -0.2
Current: -18.03
-18.55
-0.2
EV-to-Revenue 12.67
EV-to-Revenue range over the past 10 years
Min: 3.1, Med: 9.8, Max: 75.1
Current: 12.67
3.1
75.1
Current Ratio 7.73
Current Ratio range over the past 10 years
Min: 2.53, Med: 7.73, Max: 19.65
Current: 7.73
2.53
19.65
Quick Ratio 7.73
Quick Ratio range over the past 10 years
Min: 2.53, Med: 7.73, Max: 19.65
Current: 7.73
2.53
19.65
Days Sales Outstanding 53.87
Days Sales Outstanding range over the past 10 years
Min: 16.8, Med: 55.76, Max: 64.98
Current: 53.87
16.8
64.98
Days Payable 43.24
Days Payable range over the past 10 years
Min: 35.6, Med: 69.99, Max: 272.52
Current: 43.24
35.6
272.52

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -32.90
3-Year Share Buyback Rate range over the past 10 years
Min: -40.4, Med: -30.95, Max: -21.6
Current: -32.9
-40.4
-21.6

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 8.10
Price-to-Tangible-Book range over the past 10 years
Min: 1.43, Med: 6.81, Max: 12.43
Current: 8.1
1.43
12.43
Price-to-Median-PS-Value 1.01
Price-to-Median-PS-Value range over the past 10 years
Min: 0.25, Med: 0.96, Max: 10.68
Current: 1.01
0.25
10.68
Earnings Yield (Joel Greenblatt) % -6.19
Earnings Yield (Greenblatt) range over the past 10 years
Min: -467.4, Med: -32.85, Max: -6.01
Current: -6.19
-467.4
-6.01

More Statistics

Revenue (TTM) (Mil) $ 160.58
EPS (TTM) $ -1.79
Beta 3.12
Volatility % 95.88
52-Week Range $ 7.73 - 26.77
Shares Outstanding (Mil) 75.48

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y